Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C

2017 ◽  
Vol 24 (12) ◽  
pp. 1098-1106 ◽  
Author(s):  
N. Kawagishi ◽  
G. Suda ◽  
M. Onozawa ◽  
M. Kimura ◽  
O. Maehara ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Virus Reactivation ◽  
Hepatitis B Virus Reactivation ◽  
Direct Acting Antiviral ◽  
Antiviral Therapies ◽  
B Virus ◽  
Direct Acting

scholarly journals Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection

2017 ◽  
Vol 67 (5) ◽  
pp. 1106-1108 ◽  
Author(s):  
Naoki Kawagishi ◽  
Goki Suda ◽  
Masahiro Onozawa ◽  
Megumi Kimura ◽  
Osamu Maehara ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Therapy ◽  
Hbv Infection ◽  
Virus Reactivation ◽  
Hepatitis B Virus Reactivation ◽  
Direct Acting Antiviral ◽  
B Virus ◽  
Direct Acting

scholarly journals Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection

2017 ◽  
Vol 4 (1) ◽  
Author(s):  
Chen-Hua Liu ◽  
Chun-Jen Liu ◽  
Tung-Hung Su ◽  
Yu-Jen Fang ◽  
Hung-Chih Yang ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Agents ◽  
Hbv Reactivation ◽  
Virus Reactivation ◽  
Hepatic Decompensation ◽  
Hepatitis B Virus Reactivation ◽  
Direct Acting Antiviral ◽  
B Virus ◽  
Direct Acting

Abstract Background Little is known about the risk of hepatitis B virus (HBV) reactivation in patients receiving interferon (IFN)-free direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV). Methods Patients who were seropositive for HBV core antibody and who received IFN-free DAAs for HCV were enrolled. Hepatitis B virus reactivation was defined as reappearance of serum HBV deoxyribonucleic acid (DNA) ≥100 IU/mL in patients with baseline undetectable viral load, or ≥2 log10 IU/mL increase of HBV DNA in patients with baseline detectable viral load. Hepatitis B virus-related alanine aminotransferase (ALT) flare was defined as ALT ≥5 times upper limit of normal or ≥2 times of the baseline level. Hepatitis B virus-related hepatic decompensation was defined as presence of jaundice, coagulopathy, hepatic encephalopathy, or ascites. Results Compared with no HBV reactivation in 81 HBV surface antigen (HBsAg)-negative patients, 2 of 12 HBsAg-positive patients had HBV reactivation (0% [confidence interval {95% CI}, 0%–4.5%] vs 16.7% [95% CI, 4.7%–44.8%], P = .015). No patients had ALT flare or hepatic decompensation. Baseline HBsAg level at a cutoff value of 500 IU/mL was associated with HBV reactivation in HBsAg-positive patients. There was no HBsAg seroreversion in HBsAg-negative patients. Conclusions Hepatitis B virus reactivation is limited to HBsAg-positive patients receiving IFN-free DAAs for HCV. Higher baseline HBsAg levels are associated with HBV reactivation. The risk of ALT flares or hepatic decompensation is low in these patients.

Sign in / Sign up

Export Citation Format

Share Document